Thursday, May 19, 2022, 12:00 PM - 1:30 PM ET   -  Register ►

 

Activity Description

Expert pharmacist clinicians discuss the latest on emerging therapies for atopic dermatitis, strategies to engage patients in shared-decision making, and updates on vaccination best practices in immunocompromised patients in a CE-certified program featuring a live 90-minute webinar with downloadable slides.

Target Audience

The target audience for this activity is pharmacists, including community, ambulatory care, primary care, and clinical pharmacists who care for patients with atopic dermatitis, and pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Learning Objectives

Upon completion of this activity, the participant will be able to:

• Describe the underlying pathophysiology of moderate to severe AD, including inflammatory pathways and associated drug targets.
• Summarize the safety and efficacy of current and emerging targeted treatments for moderate to severe AD in children, adolescents, and adults.
• Incorporate shared decision-making and patient engagement into treatment selection for moderate to severe AD.
• Identify recommendations and best practices for herpes zoster and COVID-19 vaccination in patients with AD who are receiving immunosuppressants and immunomodulatory therapies.

Faculty

Sarah Lant, PharmD
Clinical Pharmacist Specialist
UChicago Medicine
Chicago, Illinois

Jamie L. McConaha, PharmD, NCTTP, BCACP, CDCES
Associate Professor of Pharmacy Practice
Duquesne University Mylan School of Pharmacy
Pittsburgh, Pennsylvania

CE Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-160-L01-P has been assigned to this live knowledge-based activity (initial release date 5/19/2022). This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. Faculty disclosures will be provided prior to the start of the CE activity.

Funding

This activity is supported by an educational grant from Incyte Corporation.

 

The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.